ORBITA Study: 60 Second Insights
Published: 03 August 2018
-
Views:
1542
-
Likes:
7
-
Views:
1542
-
Likes:
7
-
Up Next
-
31sPart 3 | Session 1 Gregg Stone
-
43sPart 3 | Session 2 Ajay Kirtane
-
1m 6sPart 3 | Session 3 Darrel Francis
-
1m 16sPart 3 | Session 4 Rasha Al-Lamee
-
39sPart 4 | Session 1 Gregg Stone
-
31sPart 4 | Session 2 Ajay Kirtane
-
52sPart 4 | Session 3 Darrel Francis
-
1m 12sPart 4 | Session 4 Rasha Al-Lamee
-
21sPart 5 | Session 1 Gregg Stone
-
18sPart 5 | Session 2 Ajay Kirtane
-
33sPart 5 | Session 3 Darrel Francis
-
1m 9sPart 5 | Session 4 Rasha Al-Lamee
-
13sPart 6 | Session 1 Gregg Stone
-
39sPart 6 | Session 2 Ajay Kirtane
-
56sPart 6 | Session 3 Darrel Francis
-
1m 11sPart 6 | Session 4 Rasha Al-Lamee
-
1m 11sPart 7 | Session 1 Gregg Stone
-
34sPart 7 | Session 2 Ajay Kirtane
-
1m 6sPart 7 | Session 3 Darrel Francis
-
1m 4sPart 7 | Session 4 Rasha Al-Lamee
-
28sPart 1 | Session 1 Gregg Stone Gregg Stone
-
49sPart 1 | Session 2 Ajay Kirtane Ajay J Kirtane
-
1m 1sPart 1 | Session 3 Darrel Francis Darrel P Francis
-
37sPart 1 | Session 4 Rasha Al-Lamee Rasha Al-Lamee
-
1m 1sPart 2 | Session 1 Gregg Stone Gregg Stone
-
46sPart 2 | Session 2 Ajay Kirtane Ajay J Kirtane
-
1m 8sPart 2 | Session 3 Darrel Francis Darrel P Francis
Overview
A short series of 60-second insight videos on the ORBITA Study. Hear the expert views in under one minute!
More from this programme
Part 1
Can you describe the ORBITA study in your own words?
Part 2
Why do you think that ORBITA failed to show a significant improvement in exercise capacity post PCI?
Part 3
After the results of ORBITA should we stop stenting?
Part 4
What was the biggest weakness of ORBITA?
Part 5
What is the biggest strength of ORBITA?
Part 6
How has ORBITA affected your clinical practice?
Part 7
Is there a need for further studies?
Faculty Biographies
Rasha Al-Lamee
Interventional Cardiology Consultant
Dr Rasha Al-Lamee is an interventional cardiology consultant at Imperial College Healthcare NHS Trust, London, UK.
Dr Al-Lamee studied at the University of Oxford and University College London. She completed her training in clinical cardiology on the north-west London cardiology rotation in 2013, and completed her PhD at Imperial College London in 2018.
Dr Al-Lamee’s research interests are complex coronary intervention, coronary physiology and invasive intravascular assessment. She designed, conducted and led the ORBITA trial and is lead author of the primary publication in The Lancet. Dr Al-Lamee has more than 50 peer-reviewed publications and has presented at international cardiology conferences worldwide.